A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Summary

The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of participants with moderate to severe plaque-type psoriasis.

Timeline

Start

2023-02-10

Primary completion

2023-08-09

Completion

2024-08-01

Outcome

Met primary endpoint

release “has met all the primary endpoints and key secondary endpoints in the Phase 3 registrational study (CLEAR-1) in Chinese subjects with moderate to severe plaque psoriasis.” innoventbio.com ↗

Drugs

Indications